Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Tacrolimus 8Methotrexate 7Cyclophosphamide 7Mycophenolic Acid 6Sirolimus 5Busulfan 5fludarabine phosphate 4fludarabine 4Peripheral Blood Stem Cell Transplantation 4Melphalan 3Cyclosporine 3thymoglobulin 2ibrutinib 2Whole-Body Irradiation 2Vorinostat 2Filgrastim 2Antilymphocyte Serum 2plerixafor 1carfilzomib 1aldesleukin 1Transplantation Conditioning 1Thiotepa 1Pentostatin 1Mesna 1Leukocyte Count 1KRN 7000 1Hematopoietic Stem Cell Transplantation 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Graft vs Host Disease × Calcineurin Inhibitors × Clear all
NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Regimmune Corporation

Phase 1/2 Completed
68 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡